Loading…
← CockpitCompetitor Analysis › ANIP ANI Pharmaceuticals, Inc.Open in the cockpit ↗

ANI Pharmaceuticals, Inc.ANIPCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Makes and markets generic and branded specialty pharmaceuticals, including rare disease drugs.

Momentum neutral 42
Mkt cap
$1.62B
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$35.4M
20-day average traded
Fwd P/E
7.5×
forward earnings
ROIC−WACC
+8.7 pp
WACC 6.8%
Hurdle
-41 pp
Req g minus delivered
Next earnings
100 days
26 Feb 2027
Close · USD$71.47
1D+2.1%
1W+0.5%
1M-1.6%
3M-7.6%
6M-12.8%
YTD-9.5%
1Y-12.8%
ATR %3.2%
Beta0.25
52w lowhigh18.6% off high

What ANI Pharmaceuticals does

Makes and markets generic and branded specialty pharmaceuticals, including rare disease drugs.

Earns from three sources: generic drugs, often hard-to-make or niche, sold to wholesalers and pharmacies; brands led by Cortrophin Gel, a corticotropin drug doctors use for flare-ups in conditions such as arthritis and lupus; and manufacturing for other drugmakers. The 2024 purchase of Alimera Sciences added eye-care products.

Products and services

  • Generic drugs (broad portfolio)
  • Branded rare disease drug Cortrophin Gel
  • Contract manufacturing

Customers

  • Pharmacies/wholesalers
  • Specialty and rare disease physicians

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Generic and specialty pharmaceuticals

What could go right

  • Cortrophin Gel branded revenue growth
  • Generic pipeline launches

What could go wrong

  • Generic drug price erosion
  • Reliance on Cortrophin for margin growth

Moat: narrow (regulatory licence, distribution, scale). Diversified generics base plus a growing branded rare-disease franchise with regulatory exclusivity.

Headquarters: Baudette, Minnesota, US · Founded: 1993 · Employees: 970

Named competitors

ANI Pharmaceuticals at a glance

Size ANI Pharmaceuticals (ANIP) is a United States Health Care company (Biotechnology) with a market value of $1.62B, the 1907th largest of 3,085 United States companies the cockpit tracks. Shares closed at $71.47 on 18 Nov 2026.

Performance Over six months the shares fell 12.8%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 25.9% over the last twelve months (peer median +23.4%); the operating margin is 15.3% (peer median 3.4%).

Valuation It trades at 7.5× forward earnings against a peer median of 37.0× (2nd cheapest of 9).

Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +33%, so the hurdle is -41 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.7 points above its cost of capital (6.8% WACC).

Credit ANI Pharmaceuticals has 1 bond outstanding ($316M).

Short interest Short interest is 15.6% of the free float (30 Oct 2026).

Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 91ANIP 86
Six months, rebased to 100: ANI Pharmaceuticals against the median of its 20 peers (local-currency closes).

ANI Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.04B$883M$614M$487M$316M
Revenue growth—+44%+26%+54%—
Gross profit$553M$451M$296M$246M$121M
EBITDA$242M$173M$69.9M$109M$31.2M
Net income$109M$71.4M-$18.5M$18.8M-$47.9M
Free cash flow$205M$171M$47.8M$110M-$40.1M
Capital expenditure$29.3M$34.3M$17.0M$18.5M$16.5M
Total debt$607M$628M$649M$315M$289M

Quarterly statements and history in the cockpit →

ANI Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%ALVO6882226949600226PPGNVIR145020NRIXPGENKLRAKRSASTOKRXRX087010MSB688046ZBIO2637ANIP6-month return →1-month return →
Up and to the right = strong over both horizons. ANI Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%20×40×60×ALVO688222600226PPGN145020PGEN6880462637ANIPRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ANI Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%688222145020688046ANIPGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. ANI Pharmaceuticals is the large dot.

ANI Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (ANIP vs AMRX vs TEVA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
ANI Pharmaceuticals ANIP$1.62B-13%+26%15%7.5×-7.6%
Amneal Pharmaceuticals AMRX$7.62B+79%+9%16%19.2×17.2%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%

How ANI Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ANI Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureANIPPeer medianRank in peer set
1-month return-1.6%-8.0%8th highest of 21
6-month return-12.8%-4.6%9th lowest of 20
Distance from 52-week high-18.6%-44.5%2nd highest of 21
Revenue growth (TTM)+25.9%+23.4%8th highest of 19
Operating margin15.3%3.4%7th highest of 19
Forward P/E7.5×37.0×2nd cheapest of 9
Growth the price implies (Req g, 7 yrs)-7.6%33.0%2nd least demanding of 4
Growth delivered (Del g)+33.5%+16.8%highest of 4
Hurdle (Req g minus delivered)-41.1 pp+8.1 ppleast demanding of 4
ROIC minus cost of capital+8.7 pp-5.9 pp3rd highest of 15
EV / EBITDA7.4×19.5×2nd cheapest of 6
Net debt / EBITDA0.7×-0.9×4th least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%7.5×-7.6%+33.5%
Alvotech ALVOUnited States$1.62B+38%-14%12%22.6×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%73.2×33.2%+16.8%
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%n/an/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%27.6×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%52.1×n/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%n/an/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%18.1×-12.1%+15.0%
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%n/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%7.3×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%n/an/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%n/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%n/an/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%n/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%51.9×33.0%+24.8%
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%n/an/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%46.4×n/an/a

ANI Pharmaceuticals bonds and credit

ANI Pharmaceuticals has 1 bond outstanding with $316M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are ANI Pharmaceuticals's main competitors?
Named competitors: Amneal Pharmaceuticals (AMRX), Teva Pharmaceutical (TEVA). The cockpit's measured peer set (industry) also includes Alvotech (ALVO), Hitgen (688222.SS), PELL Bio-Med Technology (6949.TW), Zhejiang Hengtong (600226.SS), PolyPeptide (PPGN.SW), Vir Biotechnology (VIR).
Is ANI Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 7.5× against a peer median of 37.0×, 2nd cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +33%, so the hurdle is -41 pp: the price already allows for a slowdown.
How has ANI Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -12.8% against -4.6% for the median peer; over one year -12.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.